Condition
Location

11 Growth Hormone Deficiency Trials

Power is an online platform that helps thousands of Growth Hormone Deficiency patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Image of trial facility.

Weekly Somapacitan vs Daily Norditropin® for Growth Hormone Deficiency

Oklahoma City, Oklahoma
This trial is testing a new weekly growth hormone medicine, somapacitan, in children who lack enough growth hormone. The goal is to see if somapacitan works well and is safe. The study will last several years with regular clinic visits. Somapacitan is intended for once weekly administration for treatment of both adults and children with growth hormone deficiency.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:2 - 11
Sex:All
200 Participants Needed
Image of trial facility.

LUM-201 for Growth Hormone Deficiency

Kansas City, Missouri
This is a multi-national trial. The trial aims to study the long-term safety of LUM-201 in subjects with Idiopathic Pediatric Growth Hormone Deficiency (iPGHD). This study will also assess pharmacodynamics and efficacy response to therapy with LUM-201.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:5 - 14
Sex:All
60 Participants Needed
Image of trial facility.

LUM-201 for Human Growth Hormone Deficiency

Kansas City, Missouri
This trial studies the effects of LUM-201, an oral medicine, in children with growth hormone deficiency who have already been treated with growth hormone therapy. The medicine helps their bodies produce more growth hormone to aid in their growth.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:3 - 13
Sex:All
18 Participants Needed
Image of trial facility.

Weekly Growth Hormone for Growth Hormone Deficiency

Fort Worth, Texas
The purpose of this study is to evaluate the efficacy and safety of weekly GenSci004 compared with daily Genotropin in treatment-naive children with growth failure due to GHD.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 3
Age:3 - 12
Sex:All
162 Participants Needed
Image of trial facility.

Lonapegsomatropin for Growth Hormone Deficiency

Dallas, Texas
This is a phase 3 open-label multicenter extension study designed to evaluate the long-term safety and efficacy of Lonapegsomatropin administered once-weekly. The study participants are adults (males and females) with confirmed growth hormone deficiency (GHD) having completed the treatment period in study TCH-306 (foresiGHt).
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:23 - 81
Sex:All
233 Participants Needed
Image of trial facility.

Somatropin for Growth Hormone Deficiency and Concussion

Minneapolis, Minnesota
This trial is testing if giving extra growth hormone can help improve the quality of life for adults who have low growth hormone levels and mild brain injuries. Growth hormone treatment has been shown to improve quality of life in adults with growth hormone deficiency.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:21 - 55
Sex:All
172 Participants Needed
Image of trial facility.

Growth Hormone Replacement for Gulf War Illness

Houston, Texas
This trial is testing if giving synthetic growth hormone to veterans with Gulf War Illness and growth hormone deficiency can reduce body fat and improve their symptoms. The study will check if this treatment is safe and effective over several months. If successful, it could lead to better care for these veterans. Growth hormone (GH) treatment has been shown to increase height velocity in children with Prader-Willi syndrome, decrease weight-for-height index values and body fat mass, and have a positive effect on lean body mass during therapy.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 64
Sex:All
20 Participants Needed
Image of trial facility.

Growth Hormone Therapy for Human Growth Hormone Deficiency

Dearborn, Michigan
This is a randomized, double-blind, placebo-controlled, parallel-group trial with an open-label extension to evaluate the efficacy of growth hormone (GH) on cognitive functions of retired professional football players with growth hormone deficiency (GHD).
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 76
Sex:Male
42 Participants Needed
Image of trial facility.

Tesamorelin for HIV-Related Lipodystrophy

New York, New York
In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity. This study is a single arm prospective study of tesamorelin therapy of patients with HIV lipodystrophy. Subjects will do body composition testing, adipose tissue biopsy, metabolic rate measurements and insulin sensitivity assessment before, 6 and 12 months after daily injections of tesamorelin 2 mg by subcutaneous injection.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 68
Sex:All
24 Participants Needed
Image of trial facility.

Growth Hormone + Liraglutide for Metabolic Health Improvement

New York, New York
This is a randomized, placebo-controlled, cross-over study with 4 arms. Healthy and GH deficient adults ages 18-45 years will be studied. Arms will consist of 21-day treatment periods and be separated by 8-week washout periods. Subjects will receive, in random order: i) GH alone, ii) GH with liraglutide, iii) liraglutide alone and iv) placebo. Each phase of the study will consist of a 7-day baseline period including 2 days of testing and 21 days on therapy with visits on days 2, 7, 14 and 21. Testing before, during and at the completion of each arm will include blood sampling and assessments of insulin resistance, energy expenditure and body composition.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 45
Sex:All
40 Participants Needed
Image of trial facility.

Growth Hormone Therapy for Pseudohypoparathyroidism

Hartford, Connecticut
We, the researchers, are following the natural history of Albright hereditary osteodystrophy. We have found that growth hormone deficiency is very common in patients with pseudohypoparathyroidism type 1A, which falls under the broader condition termed Albright hereditary osteodystrophy. Patients with pseudohypoparathyroidism type 1A typically are short and obese. Some of these patients are not short during childhood, but due to a combination of factors, they end up short as adults. We are evaluating the effect of growth hormone treatment in those patients with pseudohypoparathyroidism type 1A who are found to be growth hormone deficient (under R01 FD002568, IND 67148, which ended); those who are growth hormone sufficient and were found to have a positive clinical response to growth hormone in a prior clinical trial (under R01 FD00FD003409, IND 67148, which ended); or those who meet the criteria of idiopathic short stature or SGA. We are also evaluating neurocognitive and psychosocial functioning in participants with AHO in order to determine the specific impairments that are most common in the condition and to determine the best approach toward management. Funding source -- Growth hormone study: FDA OOPD \[R01 FD003409 (which has ended) and R01 FD002568 (which has ended)\] Cognitive/behavior: NICHD R21 HD078864 (which has ended)
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:2 - 89
Sex:All
600 Participants Needed
Page 1 of 1+

Frequently Asked Questions

How much do Growth Hormone Deficiency clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Growth Hormone Deficiency clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Growth Hormone Deficiency trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Growth Hormone Deficiency is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Growth Hormone Deficiency medical study ?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Growth Hormone Deficiency clinical trials ?

Most recently, we added Somatropin for Growth Hormone Deficiency and Concussion, Growth Hormone Replacement for Gulf War Illness and Weekly Growth Hormone for Growth Hormone Deficiency to the Power online platform.

Other People Viewed

AN4005 for Advanced Cancer

Rifaximin for Gastroparesis

Baricitinib for Pyoderma Gangrenosum

Belatacept for Heart Transplant

Senolytic Therapy for Alzheimer's Disease

AV-001 for COVID-19

Stereotactic Body Radiation Therapy for Cancer

Pemigatinib for Bladder Cancer

CART-ddBCMA for Multiple Myeloma

Tempol for Treatment Toxicities

One-Stage vs Two-Stage Orchidopexy for Undescended Testicles

Tretinoin + Arsenic Trioxide (+/- Gemtuzumab) for Leukemia

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top